Cargando…

A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.

Fifty-two previously untreated patients with advanced non-small-cell lung cancer (NSCLC) were treated on a 14 day cycle with cisplatin (60 mg m-2 i.v.) and vindesine (3 mg m-2 i.v.) on day 1, followed by a 3 day continuous infusion of 5-fluorouracil (800 mg m-2 day-1) starting on day 8. An overall r...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, T., Ikegami, H., Nakamura, S., Kawase, T., Nishikawa, H., Yokota, S., Yoshida, M., Tachibana, T., Igarashi, T., Komuta, K., Higashino, K.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074391/
https://www.ncbi.nlm.nih.gov/pubmed/8624270
_version_ 1782137956950081536
author Nakano, T.
Ikegami, H.
Nakamura, S.
Kawase, T.
Nishikawa, H.
Yokota, S.
Yoshida, M.
Tachibana, T.
Igarashi, T.
Komuta, K.
Higashino, K.
author_facet Nakano, T.
Ikegami, H.
Nakamura, S.
Kawase, T.
Nishikawa, H.
Yokota, S.
Yoshida, M.
Tachibana, T.
Igarashi, T.
Komuta, K.
Higashino, K.
author_sort Nakano, T.
collection PubMed
description Fifty-two previously untreated patients with advanced non-small-cell lung cancer (NSCLC) were treated on a 14 day cycle with cisplatin (60 mg m-2 i.v.) and vindesine (3 mg m-2 i.v.) on day 1, followed by a 3 day continuous infusion of 5-fluorouracil (800 mg m-2 day-1) starting on day 8. An overall response rate of 40.4% was observed in 47 evaluable patients, which included one complete response and 18 partial responses. Responses were achieved in 61.1% of stage 3 patients and 27.6% of stage 4 patients. The median progression-free interval was 19.3 weeks, and median survival time was 41.6 weeks (47.1 weeks for patients with stage 3 disease and 38.7 weeks for those with stage 4 disease). Toxicity was well tolerated. Gastrointestinal and renal toxicities did not exceed WHO grade 2. Grade 3 or 4 leucopenia and anaemia occurred in nine (19%) and four (9%) patients respectively, but only grade 2 thrombocytopenia was observed. Phlebitis at the infusion site was observed in 24 patients (53%). This treatment programme achieved a response rate similar to other active combination regimens for the treatment of advanced NSCLC, and was less toxic.
format Text
id pubmed-2074391
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20743912009-09-10 A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group. Nakano, T. Ikegami, H. Nakamura, S. Kawase, T. Nishikawa, H. Yokota, S. Yoshida, M. Tachibana, T. Igarashi, T. Komuta, K. Higashino, K. Br J Cancer Research Article Fifty-two previously untreated patients with advanced non-small-cell lung cancer (NSCLC) were treated on a 14 day cycle with cisplatin (60 mg m-2 i.v.) and vindesine (3 mg m-2 i.v.) on day 1, followed by a 3 day continuous infusion of 5-fluorouracil (800 mg m-2 day-1) starting on day 8. An overall response rate of 40.4% was observed in 47 evaluable patients, which included one complete response and 18 partial responses. Responses were achieved in 61.1% of stage 3 patients and 27.6% of stage 4 patients. The median progression-free interval was 19.3 weeks, and median survival time was 41.6 weeks (47.1 weeks for patients with stage 3 disease and 38.7 weeks for those with stage 4 disease). Toxicity was well tolerated. Gastrointestinal and renal toxicities did not exceed WHO grade 2. Grade 3 or 4 leucopenia and anaemia occurred in nine (19%) and four (9%) patients respectively, but only grade 2 thrombocytopenia was observed. Phlebitis at the infusion site was observed in 24 patients (53%). This treatment programme achieved a response rate similar to other active combination regimens for the treatment of advanced NSCLC, and was less toxic. Nature Publishing Group 1996-05 /pmc/articles/PMC2074391/ /pubmed/8624270 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Nakano, T.
Ikegami, H.
Nakamura, S.
Kawase, T.
Nishikawa, H.
Yokota, S.
Yoshida, M.
Tachibana, T.
Igarashi, T.
Komuta, K.
Higashino, K.
A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
title A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
title_full A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
title_fullStr A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
title_full_unstemmed A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
title_short A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
title_sort phase ii study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. osaka lung cancer chemotherapy study group.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074391/
https://www.ncbi.nlm.nih.gov/pubmed/8624270
work_keys_str_mv AT nakanot aphaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT ikegamih aphaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT nakamuras aphaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT kawaset aphaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT nishikawah aphaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT yokotas aphaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT yoshidam aphaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT tachibanat aphaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT igarashit aphaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT komutak aphaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT higashinok aphaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT nakanot phaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT ikegamih phaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT nakamuras phaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT kawaset phaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT nishikawah phaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT yokotas phaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT yoshidam phaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT tachibanat phaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT igarashit phaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT komutak phaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup
AT higashinok phaseiistudyofcisplatinvindesineandcontinuouslyinfused5fluorouracilinthetreatmentofadvancednonsmallcelllungcancerosakalungcancerchemotherapystudygroup